Welcome to our dedicated page for AIKI news (Ticker: aiki), a resource for investors and traders seeking the latest updates and insights on AIKI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AIKI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AIKI's position in the market.
AIkido Pharma Inc. (Nasdaq: AIKI) will present at the LD 500 investor conference on September 3, 2020, at 11:20 a.m. ET. CEO Anthony Hayes will speak to a live audience. The event, happening from September 1-4, is notable for being accessible to all attendees due to pandemic restrictions on physical gatherings. AIkido specializes in anti-cancer therapeutics and collaborates with prestigious institutions like The University of Texas at Austin and Wake Forest University to develop innovative therapeutic options for various cancers.
AIkido Pharma Inc. (Nasdaq: AIKI) has announced an extension of its exclusive option agreement with the University of Maryland, Baltimore, regarding the technology contained in Patent 10,434,116 for treating coronavirus infections. This option, originally disclosed on March 6, 2020, has been extended until December 2, 2020. The agreement's other terms remain unchanged. This patent was developed with government support under Grant Number AI095569 from the National Institutes of Health, which retains certain rights.
AIkido Pharma Inc. (Nasdaq: AIKI) announced on July 31, 2020, that it has regained compliance with the NASDAQ's minimum bid price requirement of $1.00. The company met this requirement by maintaining a closing bid price of at least $1.00 for ten consecutive business days. This development supports AIkido's continued presence on the NASDAQ Capital Market, important for its operational stability and investor confidence.
AIkido Pharma Inc. (Nasdaq: AIKI) announced progress in identifying antiviral compounds aimed at combating COVID-19. Following an April 2020 agreement with the University of Maryland, researchers discovered a human protein complex linked to virus replication. Using a method called SILCS, they found compounds that inhibit various viruses, including COVID-19 and Influenza. CEO Anthony Hayes emphasized the role of machine learning in accelerating drug research, ultimately aiming to develop compounds that effectively treat multiple viral infections.
AIkido Pharma Inc. (Nasdaq: AIKI) provided an update on its machine learning-driven pancreatic cancer research, identifying 100 candidate markers associated with the disease. In collaboration with The University of Texas Southwestern Medical Center and Cogia BioTech, the Company aims to enhance diagnostic procedures and tailor drug treatments for patients. CEO Anthony Hayes emphasized the significance of machine learning in oncology drug development. AIkido also develops therapies for various cancers and a broad-spectrum antiviral platform targeting multiple viruses.